Developmentally arrested structures preceding cerebellar tumors in von Hippel-Lindau disease

Modern Pathology

Volumn 24, Issue 8, 2011, Pages 1023-1030

  Shively, Sharon B ^a,b   Falke, Eric A ^c   Li, Jie ^c   Tran, Maxine G B ^d   Thompson, Eli R ^a   Maxwell, Patrick H ^e   Roessler, Erich ^f   Oldfield, Edward H ^g   Lonser, Russell R ^a   Vortmeyer, Alexander O ^c  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

hemangioblastoma; tumor precursors; von Hippel Lindau disease

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ADOLESCENT; ADULT; ARTICLE; CELL DIFFERENTIATION; CENTRAL NERVOUS SYSTEM; CEREBELLAR DEVELOPMENTALLY ARRESTED STRUCTURAL ELEMENT; CEREBELLUM; CEREBELLUM TUMOR; CLINICAL ARTICLE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; STEM CELL; TOPOGRAPHY; VON HIPPEL LINDAU DISEASE;

ADOLESCENT; ADULT; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL DIFFERENTIATION; CEREBELLAR NEOPLASMS; CEREBELLUM; FEMALE; HEMANGIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; VON HIPPEL-LINDAU DISEASE;

EID: 79961027723     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.61     Document Type: Article

References (51)

1. Lamiell JM, Salazar FG, Hsia YE. von Hippel-Lindau disease affecting 43 members of a single kindred. Medicine (Baltimore) 1989;68:1-29. (Pubitemid 19041250)
2. Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-682.
3. Cushing H, Bailey P. Tumors Arising from the Blood-Vessels of the Brain. Angiomatous Malformations and Hemangioblastomas. Charles C. Thomas: Springfield, 1928.
4. Lindau A. Discussion on vascular tumors of the brain and spinal cord. Proc R Soc Med 1931;24:363-370.
5. Stein AA, Schilp AO, Whitfield RD. The histogenesis of hemangioblastoma of the brain. J Neurosurg 1960;17:751-761.
6. Glasker S, Li J, Xia JB, et al. Hemangioblastomas share protein expression with embryonal hemangioblast progenitor cell. Cancer Res 2006;66:4167-4172.
7. Lonser RR, Glenn GM, Walther M, et al. von Hippel-Lindau disease. Lancet 2003;361:2059-2067. (Pubitemid 36695052)
8. Plate K, Vortmeyer A, Zagzag D, et al. Von Hippel-Lindau disease and haemangioblastoma. In: Louis D, Ohgaki H, Wiestler O, Cavenee W (eds). WHO Classification of Tumours of the Nervous System, Vol., 4th edn. IARC Press: Lyon, 2007, pp 215-217.
9. Glasker S. Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer 2005;4:37-42. (Pubitemid 40754843)
10. Mack FA, Rathmell WK, Arsham AM, et al. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell 2003;3:75-88. (Pubitemid 37443892)
11. Haase VH. The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting. Semin Cell Dev Biol 2005;16:564-574. (Pubitemid 41247880)
12. Nyhan MJ, O'Sullivan GC, McKenna SL. Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans 2008;36(Part 3):472-478. (Pubitemid 351839358)
13. Kapitsinou PP, Haase VH. The VHL tumor suppressor and HIF: insights from genetic studies in mice. Cell Death Differ 2008;15:650-659. (Pubitemid 351405068)
14. Simon MC, Keith B. The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 2008;9:285-296. (Pubitemid 351430845)
15. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000;275:25733-25741.
16. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000;2:423-427.
17. Maxwell PH, Ratcliffe PJ. Oxygen sensors and angiogenesis. Semin Cell Dev Biol 2002;13:29-37. (Pubitemid 35418312)
18. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-275. (Pubitemid 29246458)
19. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 1996;93:10595-10599. (Pubitemid 26333032)
20. Mandriota SJ, Turner KJ, Davies DR, et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002;1:459-468. (Pubitemid 41039126)
21. Panchision DM. The role of oxygen in regulating neural stem cells in development and disease. J Cell Physiol 2009;220:562-568.
22. Gustafsson MV, Zheng X, Pereira T, et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005;9:617-628. (Pubitemid 41555144)
23. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev 2006;20:557-570. (Pubitemid 43345322)
24. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ 2008;15:628-634. (Pubitemid 351405065)
25. Vortmeyer AO, Yuan Q, Lee YS, et al. Developmental effects of von Hippel-Lindau gene deficiency. Ann Neurol 2004;55:721-728. (Pubitemid 38544333)
26. Vortmeyer AO, Frank S, Jeong SY, et al. Developmental arrest of angioblastic lineage initiates tumorigenesis in von Hippel-Lindau disease. Cancer Res 2003;63: 7051-7055. (Pubitemid 37413438)
27. Shively SB, Beltaifa S, Gehrs B, et al. Protracted haemangioblastic proliferation and differentiation in von Hippel-Lindau disease. J Pathol 2008;216: 514-520.
28. Vortmeyer AO, Huang S, Lubensky I, et al. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004;89:1934-1938. (Pubitemid 38507955)
29. Abel TW, Baker SJ, Fraser MM, et al. Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 2005;64:341-349. (Pubitemid 40489561)
30. Blumenthal GM, Dennis PA. PTEN hamartoma tumor syndromes. Eur J Hum Genet 2008;16:1289-1300.
31. Brugarolas J, Kaelin Jr WG. Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. Cancer Cell 2004;6:7-10. (Pubitemid 38903157)
32. Chan CC, Koch CA, Kaiser-Kupfer MI, et al. Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol 2002;198:14-20. (Pubitemid 34966202)
33. Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med 2006;355:1345-1356.
34. Majno G, Joris I. Cells, Tissues, and Disease: Principles of General Pathology, 2nd edn. Oxford University Press: New York, 2004, p.pp xxviii, 1005.
35. Vortmeyer AO, Tran MG, Zeng W, et al. Evolution of VHL tumourigenesis in nerve root tissue. J Pathol 2006;210:374-382. (Pubitemid 44660517)
36. Glasker S, Tran MG, Shively SB, et al. Epididymal cystadenomas and epithelial tumourlets: effects of VHL deficiency on the human epididymis. J Pathol 2006;210:32-41. (Pubitemid 44288178)
37. Mehta GU, Shively SB, Duong H, et al. Progression of epididymal maldevelopment into hamartoma-like neoplasia in VHL disease. Neoplasia 2008;10:1146-1153.
38. Gläsker S, Lonser RR, Tran MG, et al. Effects of VHL deficiency on endolymphatic duct and sac. Cancer Res 2005;65:10847-10853. (Pubitemid 41713352)
39. Rubin E, Farber JL. Pathology, 3rd edn. Lippincott-Raven: Philadelphia, PA, 1999.
40. Stevens A, Lowe JS. Pathology: Illustrated Review in Color, 2nd edn. Mosby: London, UK, 2000.
41. Kumar V, Abbas AK, Fausto N. Robbins and Cotran. Pathologic Basis of Disease. Elsevier Saunders: Philadelphia, 2005.
42. Chandrasoma P, Taylor CR. Concise Pathology, 3rd edn. Appleton and Lange: Norwalk, CT, 1998.
43. Flamme I, Krieg M, Plate KH. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2{alpha}. Am J Pathol 1998;153:25-29. (Pubitemid 28317503)
44. Zagzag D, Zhong H, Scalzitti JM, et al. Expression of hypoxia-inducible factor 1alpha in brain tumors. Cancer 2000;88:2606-2618.
45. Huber TL, Kouskoff V, Fehling HJ, et al. Haemangioblast commitment is initiated in the primitive streak of the mouse embryo. Nature 2004;432: 625-630. (Pubitemid 39626269)
46. Neumann HP, Lips CJ, Hsia YE, et al. Von Hippel-Lindau syndrome. Brain Pathol 1995;5:181-193.
47. Resche F, Moisan JP, Mantoura J, et al. Haemangioblastoma, haemangioblastomatosis, and von Hippel-Lindau disease. Adv Tech Stand Neurosurg 1993;20:197-304.
48. French VHL Study Group Richard S Campello C, Taillandier L, et al. Haemangioblastoma of the central nervous system in von Hippel-Lindau disease. J Intern Med 1998;243:547-553. (Pubitemid 28312255)
49. Takai K, Taniguchi M, Takahashi H, et al. Comparative analysis of spinal hemangioblastomas in sporadic disease and Von Hippel-Lindau syndrome. Neurol Med Chir (Tokyo) 2010;50:560-567.
50. Wanebo JE, Lonser RR, Glenn GM, et al. The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003;98:82-94. (Pubitemid 36050451)
51. Hu CJ,Wang LY, Chodosh LA, et al. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-9374. (Pubitemid 37499822)